TaiMed Biologics Completes Phase 2b Enrollment for TMB-365/380 HIV Therapy
TaiMed Biologics completes Phase 2b enrollment for TMB-365/380 HIV therapy, a dual antibody combination dosed every two months without...
Nuvalent to Present Neladalkib and Zidesamtinib Data at 2026 ASCO
Nuvalent neladalkib achieves oral presentation at 2026 ASCO for ALK-positive NSCLC, with NDA filed in April ahead of FDA...
Sapience’s lucicebtide shows 28.4-month median survival in glioblastoma Phase 2
Sapience's lucicebtide demonstrated 28.4-month median progression-free survival in newly diagnosed glioblastoma, significantly exceeding historical benchmarks i
Astegolimab’s Split Verdict: What ALIENTO’s Win and ARNASA’s Miss Reveal About COPD Trial Design
Astegolimab cut COPD exacerbations in Phase 2b but missed in Phase 3—a 14.5% gap that exposes critical flaws in...
Tedopi Plus Pembrolizumab Extends Survival in Recurrent Ovarian Cancer
Tedopi Plus Pembrolizumab extends median PFS to 4.1 months in platinum-sensitive recurrent ovarian cancer, marking the first positive randomized...
BIIB122 fails to slow motor decline in early Parkinson’s disease trial
BIIB122 fails to slow motor decline in early Parkinson's disease trial despite strong target engagement and biomarker effects.
When AI Scales Your Protocol, It Scales Every Flaw Inside It
Phesi's 2026 analysis found fewer than 1 in 3 trial protocols are linked to patient data—meaning AI tools are...
Europe’s 2030 Clinical Trial Targets Are Already Falling Behind — And the Clock Is Ticking
EMA's first 2026 quarterly report shows only 40.5% of EU trials recruiting within 200 days — far below the...
Achieve Life Sciences Presents 52-Week Safety Data for Cytisinicline
Achieve Life Sciences presents 52-week safety data for cytisinicline ahead of June 2026 FDA decision, showing low nausea rates...
Quince’s LAM-001 Shows Functional Gains in Phase 2a PH-ILD Study
LAM-001 Phase 2a study shows 67-meter walk distance gain and improved functional class in PH-ILD patients on background treprostinil...